Actome GmbH and QIAGEN announce commercial partnership
Actome and QIAGEN have signed a licensing and co-marketing agreement to jointly accelerate the commercialization of Actome’s proprietary
Protein-Interaction-Coupling (PICO) -Technology
(firmenpresse) - Freiburg, Germany, 07.1.2022
Actome GmbH, a life-science start-up company from the University of Freiburg and Hahn-Schickard, Germany has signed a license agreement and a co-marketing agreement with QIAGEN GmbH, Hilden, Germany, to jointly accelerate the market entry of Actome’s Protein-Interaction-Coupling (PICO) -Technology. The collaboration will help Actome to bring products to the market faster while providing a unique innovative feature to the QIAcuity dPCR product line of QIAGEN. Actome will market first products exclusively for use on QIAGEN’s digital PCR instruments as well as support QIAGEN in developing own products. Both partners will jointly commercialize the disruptive PICO-Technology for molecular biological research in the future.
The unique performance of Actome’s products is based on the patented PICO -Technology that detects single protein molecules and protein interaction complexes by translating protein status into DNA-barcodes. These barcodes are then detected by the method of digital PCR and decoded by a proprietary software developed by Actome. “Our PICO-Technology expands the capabilities of the QIAcuity digital PCR platform by QIAGEN from nucleic acids to proteins. The application of our technology in the fields of proteomics, molecular pathway research and biomarker discovery will help to increase our knowledge about molecular biological processes and will transform molecular biological research in an unprecedented way.” says Csaba Jeney, co-founder, CEO, and inventor of the technology.
Proteins control and direct biological processes through their interactions, the so-called interactome, by which they determine our health and wellbeing. Tools to study the interactome enable the understanding of cellular processes and open up an enormous potential for research, diagnostics and therapies. Tackling these challenges, Actome's innovative technology is a breakthrough that will revolutionize research and biomedicine. “QIAcuity is expanding into new research fields as a cost-effective and very reliable digital PCR system,” said Thomas Schweins, Senior Vice President, Head of the Life Science Business Area at QIAGEN. “The partnership with Actome extends the use of this technology to protein quantification and protein-protein interaction.”
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Actome is a privately held young life-science startup founded in 2017. The year before Dr. Jeney moved from Budapest to Freiburg to partner with Dr. Koltay and to leverage his start-up experience and the excellent environment provided by the University of Freiburg and the Hahn-Schickard research institute in Freiburg. Actome provides assay kits, bioinformatics software and services for the sensitive, highly parallel and quantitative measurement of proteins and protein interactions. The long term vision of Actome is to decode the whole interactome and to exploit these discoveries in molecular diagnostic products for personalized medicine. Actome’s first products will target the research market in the field of molecular biology with a specific focus on assay-kits for multi-omics and single cell analysis.
www.actome.de
For further information, please contact:
Dr. Peter Koltay, CEO
Phone: +49 761 203 73240
E-Mail: peter.koltay(at)actome.de
For further information, please contact:
Dr. Peter Koltay, CEO
Phone: +49 761 203 73240
E-Mail: peter.koltay(at)actome.de
Datum: 07.01.2022 - 11:51 Uhr
Sprache: Deutsch
News-ID 653301
Anzahl Zeichen: 2574
contact information:
Contact person: Peter Koltay
Town:
Freiburg
Kategorie:
Biotech
Typ of Press Release: Cooperation
type of sending: send
Date of sending: 07.01.2022
Diese Pressemitteilung wurde bisher 184 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actome GmbH and QIAGEN announce commercial partnership "
steht unter der journalistisch-redaktionellen Verantwortung von
Actome GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
